Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7941754 | 1.00 | MAPT (0.55) | MAPTSIGMAR1CYP3A4TSHRCYP2C19 | |
| SCHEMBL1974795 | 1.00 | MAPT (0.55) | MAPTSIGMAR1CYP3A4TSHRCYP2C19 | |
| SCHEMBL3898603 | 1.00 | MAPT (0.55) | MAPTSIGMAR1CYP3A4TSHRCYP2C19 | |
| Hydrochloric Acid SCHEMBL11674164 | 0.98 | MAPT (0.54) | MAPTSIGMAR1CYP3A4TSHRCYP2C19 | |
| SCHEMBL2079349 | 0.88 | MAPT (0.55) | MAPTSIGMAR1FUCA1 | |
| SCHEMBL566923 | 0.87 | MAPT (0.58) | MAPTSIGMAR1CYP3A4TSHRCYP2C19 | |
| SCHEMBL5591234 | 0.87 | MAPT (0.58) | MAPTSIGMAR1CYP3A4TSHRCYP2C19 | |
| SCHEMBL16044726 | 0.87 | MAPT (0.58) | MAPTSIGMAR1CYP3A4TSHRCYP2C19 | |
| SCHEMBL566922 | 0.87 | MAPT (0.58) | MAPTSIGMAR1CYP3A4TSHRCYP2C19 | |
| SCHEMBL16043911 | 0.87 | MAPT (0.58) | MAPTSIGMAR1CYP3A4TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4272824-A2 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-11-08 | — | — | EP | disclosed |
| EP-3622956-B9 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-27 | — | — | EP | disclosed |
| EP-3622956-B1 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-07 | — | — | EP | disclosed |